InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,200.40
(
-0.07%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.78
(
0.36%
)
Bitcoin
61,090.79
(
0.46%
)
Post# of 252390
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 33611

Thursday, 09/07/2006 8:23:32 AM

Thursday, September 07, 2006 8:23:32 AM

Post# of 252390
GTCB – This settlement indirectly affects GTC because GTC licensed its nuclear-transfer technology from ACTC. Thus, GTC may now owe certain royalties to stART Licensing (the JV of GERN and Exeter) instead of to ACTC, but this shouldn’t make any real difference.

Importantly, this outcome does not affect GTC’s lead, drug, ATryn, because the goat herd for ATryn was created using microinjection rather than nuclear transfer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up